Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Effect of Liraglutide in Obese Subjects With Moderate or Severe Obstructive Sleep Apnoea. A 32 Week Randomised, Double-blind, Placebo-controlled, Parallel Group, Multi-centre and Multinational Trial

Next Previous
Trial Profile

Effect of Liraglutide in Obese Subjects With Moderate or Severe Obstructive Sleep Apnoea. A 32 Week Randomised, Double-blind, Placebo-controlled, Parallel Group, Multi-centre and Multinational Trial

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 17 Sep 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Liraglutide (Primary)
  • Indications Obesity; Sleep apnoea syndrome
  • Focus Registrational; Therapeutic Use
  • Acronyms SCALE; SCALE-Sleep Apnoea
  • Sponsors Novo Nordisk

    • Most Recent Events

    • 04 Apr 2016 Results (pooled analysis of this and other four trials, n = 5338) assessing neuropsychiatric Safety Profile presented at The 98th Annual Meeting of the Endocrine Society.
    • 08 May 2015 According to the Novo Nordisk media release, further data from this and other three SCALE trials (see profile 193291, 193353 and 38848) expected to be presented and published in 2015.
    • 08 May 2015 According to the Novo Nordisk media release, new data from a post-hoc analysis of this and other three SCALE trials (see profile 193291, 38848 and 193353) were presented at the European Congress on Obesity (ECO).
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top